Heterocyclic derivatives for the treatment of RSV

Patent metadata

Field	Value
Publication number	US-11084796-B2
Application number	US-201716099957-A
Country	US
Kind code	B2
Filing date	May 10, 2017
Priority date	May 10, 2016
Publication date	Aug 10, 2021
Grant date	Aug 10, 2021

Abstract

Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

First claim

What is claimed is:

1. A compound of Formula 1b-1:

or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof, wherein

z is 0;
y is 1;
R 1 and R 2 are independently selected from the group consisting of R a , OR a ′, N(R a ) 2 , SR a , C(═O)R a , C(═O)OR a ′, C(═O)N(R a ) 2 , and C(═O)SR a ;
wherein two or more R 1 , R 2 , or R a groups may independently form a ring;
wherein R a is selected from the group consisting of hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, C 2-8 heterocyclyl, C 6-12 aryl, C 3-12 heteroaryl, C 1-8 alkyl-C 3-8 cycloalkyl, C 1-8 alkyl-C 2-8 heterocyclyl, C 1-8 alkyl-C 6-12 aryl, and C 1-8 alkyl-C 3-12 heteroaryl;
wherein a is 1, 2, 3 or 4; and R 8 is selected from the group consisting of —OR a ′, —N(R a ) 2 , —SR a , —SO 2 R a , —SO 2 N(R a ) 2 ; —C(O)R a , OC(O)R a , —COOR a , —C(O)N(R a ) 2 , —OC(O)N(R a ) 2 , —N(R a )C(O), —N(R a )C(O)N(R a ) 2 , —F, —Cl, —Br, —I, —CN, and —NO 2 ; and
wherein R 1 is not NH—CH2-CH2-phenyl.

2. The compound according to claim 1 wherein the compound is selected from the group consisting of:

3. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, vehicle, or excipient.

4. The pharmaceutical composition according to claim 3 wherein the compound is selected from the group consisting of:

5. The pharmaceutical composition according to claim 4 wherein the compound is selected from the group consisting of:

6. The compound according to claim 1 , wherein R 1 is selected from the group consisting of:

b is 0, 1, 2, 3, or 4,
R 9 is selected from the group consisting of —R a , —OR a ′, —N(R a ) 2 , —SR a , —SO 2 R a , —SO 2 N(R a ) 2 ; —C(O)R a , OC(O)R a , —COOR a , —C(O)N(R a ) 2 , —OC(O)N(R a ) 2 , —N(R a )C(O), —N(R a )C(O)N(R a ) 2 , —F, —Cl, —Br, —I, —CN, and —NO 2 , wherein any two or more R 9 groups may together form a ring;
wherein R 10 is selected from the group consisting of R a , C(O)R a , SO 2 R a , COOR a , and C(O)N(R a ) 2 , and wherein R 10 may form a ring with any R 1 , R 2 , R 8 , or R a groups.

7. A method of inhibiting RSV comprising administering to a patient in need thereof an effective amount of the compound of claim 1 .

8. The method according to claim 7 , wherein R 1 is selected from the group consisting of:

b is 0, 1, 2, 3, or 4,
R 9 is selected from the group consisting of —R a , —OR a ′, —N(R a ) 2 , —SR a , —SO 2 R a , —SO 2 N(R a ) 2 ; —C(O)R a , OC(O)R a , —COOR a , —C(O)N(R a ) 2 , —OC(O)N(R a ) 2 , —N(R a )C(O), —N(R a )C(O)N(R a ) 2 , —F, —Cl, —Br, —I, —CN, and —NO 2 , wherein any two or more R 9 groups may together form a ring;
wherein R 10 is selected from the group consisting of R a , C(O)R a , SO 2 R a , COOR a , and C(O)N(R a ) 2 , and wherein R 10 may form a ring with any R 1 , R 2 , R 8 , or R a groups.

9. The method according to claim 7 , wherein R 1 is a group of the formula:

10. The method according to claim 7 , wherein R 2 is C(═O)NHR a1 , wherein said R a1 is selected from the group consisting of C 3-8 cycloalkyl, C 2-8 heterocyclyl, C 6-12 aryl, and C 3-12 heteroaryl.

11. The method according to claim 7 , wherein R 2 is C(═O)NH—C 3-8 cycloalkyl.

12. The method according to claim 7 , wherein R 2 is C(═O)NHcyclohexyl.

13. The method according to claim 7 wherein the compound is selected from the group consisting of:

14. A method of treating an RSV infection, comprising administering to a patient in need thereof, an effective amount of the compound of claim 1 .

15. The method of treating an RSV infection according to claim 14 wherein the compound is administered via a route of administration selected from the group consisting of buccal, oral, intravenous, inhalation, intradermal, intramuscular, topical, subcutaneous, rectal, vaginal, parenteral, pulmonary, intranasal, and ophthalmic.

16. The method of treating an RSV infection according to claim 14 wherein the compound is selected from the group consisting of:

Assignees

• Univ Georgia State Res Found

Inventors

• Plemper Richard K
• Lee Eddy
• Vernachio John
• Bourque Elyse

Classifications

• C12N2760/18511

  Pneumovirus, e.g. human respiratory syncytial virus · CPC title

• A61K31/542

  ortho- or peri-condensed with heterocyclic ring systems · CPC title

• A61K31/5415

  ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam · CPC title

• C07D279/16 Primary

  condensed with one six-membered ring · CPC title

• A61P31/14

  for RNA viruses · CPC title